Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?
作者: Mark TrusheimMurray AitkenErnst Berndt
刊名: Forum for Health Economics & Policy, 2010, Vol.13 (1)
中文刊名: 健康经济和政策论坛, 2010, Vol.13 (1)
来源数据库: Berkeley Electronic Journal
关键词: biologicssmall moleculespharmaceuticalsinnovationprice growth
英文摘要: While much has been written about the distinctions between biologics and small molecules in terms of their scientific, manufacturing and regulatory experiences, relatively little has been published comparing their clinical and commercial experiences. Employing a data base encompassing all 96 biologics and 212 small molecules newly launched in the U.S. between 1998Q1 and 2008Q4, we compare their downstream clinical and commercial characteristics. Substantial heterogeneity occurs across therapeutic classes. Biologics are more concentrated than small molecules in their therapeutic class composition, but have obtained FDA indication approvals in 13 of 15 classes. While average delays between FDA approval and first observed sales revenues are similar, biologics are twice as likely as small...
全文获取路径:  
分享到:

×